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O-9 LOSS OF CSMD1 EXPRESSION DISRUPTS CELL MORPHOL-
OGY AND MAMMARY DUCT FORMATION WHILE ENHANCING
PROLIFERATION, MIGRATION AND INVASION
Mohamed Kamal a,b, Deborah Holliday a, Valerie Speirs a, Carmel
Toomes a, Sandra M. Bell a. a Leeds Institute of Molecular Medicine,
University of Leeds, UK. bFaculty of Science, University of Benha, Egypt
CUB and Sushi multiple domains protein 1 (CSMD1) maps to
8p23, a region deleted in many cancers, and thought to be a
tumour suppressor gene. Loss of CSMD1 expression is associated
with reduced survival in breast cancer patients. CSMD1’s function
is unknown; however, CSMD1‘s structure suggests it is involved in
signal transduction. Here, we have investigated the function of
CSMD1. CSMD1 expression was silenced in MCF10A, MDA-MB-
435 and LNCaP cell lines by shRNA and functional assays were
performed.
Loss of CSMD1 expression disrupted cell morphology and
caused 30% (p < 0.001), 32% (p = 0.03) and 56% (p < 0.001) increase
in cell proliferation of MDA-MB-435, LNCaP and MCF10A, respec-
tively, compared to controls. Also MDA-MB-435 and MCF10A
shCSMD1 cells showed reduced adhesion to matrigel (32%,
p = 0.0005 and 44%, p = 0.0006, respectively), and to fibronectin
(39%, p = 0.004 and 32%, p < 0.001, respectively). Moreover, loss
of CSMD1 expression enhanced cell migration of MDA-MB-435
and MCF10A and caused 33% (p < 0.001) increase in cell invasion
of MCF10A, compared to control. The MCF10A 3D model revealed
that loss of CSMD1 expression resulted in the development of lar-
ger poorly differentiated breast acini and impaired lumen
formation.
Loss of CSMD1 expression induced behaviour consistent with
cellular transformation. Our data supports the concept that
CSMD1 participates in signaling pathways that regulate a range
of key cellular processes involved in the suppression of a trans-
formed phenotype.
doi:10.1016/j.ejcsup.2010.06.010
O-10 HIGH TIMM17A EXPRESSION IS ASSOCIATED WITH POOR
CLINICAL OUTCOME AND UNFAVOURABLE PATHOLOGICAL
PARAMETERS IN HUMAN BREAST CANCER
Mohamed Salhab a, Neill Patani a, Wen Jiang b, Kefah Mokbel a. a St
George’s Hospital, London, UK. bUniversity Department of Surgery,
Cardiff, UK
Introduction: Mitochondrial dysfunction can be associated with
genomic instability and has been implicated in the pathogenesis
of breast cancer (BC). The mitochondrial protein, Translocase of
Inner Mitochondrial Membrane 17 homolog A (TIMM17A) contrib-
utes to a pre-protein import complex, essential for mitochondrial
function. In this study, TIMM17A mRNA expression was evaluated
in benign and malignant breast tissues and correlated with path-
ological and clinical outcomes.
Methods: BC tissues (n = 127) and normal tissues (n = 33) under-
went RNA extraction and reverse transcription, transcript levels
were determined using real-time quantitative PCR and normal-
ized against CK19. Transcript levels were compared and then ana-
lysed against tumour size, tumour grade, oestrogen receptor (ER)
status, nodal involvement, TNM stage, Nottingham Prognostic
Index (NPI) and clinical outcome over a 10 year follow-up period.
Results: Compared to normal tissue, TIMM17A mRNA expres-
sion was higher in BC (p = 0.006), TNM-1 (p = 0.05), TNM-2
(p = 0.034), NPI-2 (p = 0.041), patients with progressive disease
(p = 0.017) and those who died from BC (p = 0.026). Expression
increased with tumour grade; grade 1 versus 2 (p = 0.007), grade
1 versus 3 (p = 0.065, NS) and grade 1 versus 2 and 3 (p = 0.0048).
Higher transcript levels were associated with ER-a positivity
(p = 0.073, NS) and ER-b negativity (p = 0.015). Nodal positivity
was significantly associated with higher transcript levels
(p = 0.046). Compared to disease free patients, TIMM17A expres-
sion was significantly higher in those with progressive disease
and patients who died of BC (p = 0.037). Higher transcript levels
were significantly associated with poorer overall survival after a
median follow-up of 10 years (p = 0.010). TIMM17A expression
emerged as a strong independent predictor of overall survival in
multivariate analysis (p = 0.033).
Conclusion: TIMM17A mRNA expression is significantly associ-
ated with unfavourable pathological parameters including
tumour grade, nodal positivity, TNM stage and NPI; in addition
to adverse clinical outcomes such as progressive disease and
overall survival. TIMM17A offers utility as a prognostic marker
and a novel mitochondrial target for potential therapeutic
strategies.
doi:10.1016/j.ejcsup.2010.06.011
O-11 INHIBITING DNA METHYLATION AND HISTONE
DEACETYLATION ENHANCES RESPONSE TO DOCETAXEL IN
BREAST CANCER CELLS
Lena Kastl, Andrew C. Schofield. School of Medicine and Dentistry,
University of Aberdeen, UK
Introduction: Understanding the mechanisms of drug resis-
tance is important to improve and deliver effective therapy. Epige-
netic modifications like DNA methylation and histone
deacetylation can alter gene expression, due to gene silencing,
and may represent mechanisms of drug resistance.
Methods: Breast cancer cells (MCF-7 and MDA-MB-231), and
their docetaxel-resistant sublines, were treated with either tri-
chostatin A (TSA), 5-aza-20-deoxycytidine (decitabine) or in com-
bination. DNA methyltransferase activity and global
methylation were measured by ELISA-based assays, and histone
acetylation levels were measured by western blot. Response to
docetaxel of cells treated with inhibitors was measured using cell
viability assay. Gene expression analysis was performed using a
microarray-based quantitative PCR system. Western analysis
was used to validate gene expression changes at the protein level.
Results: Docetaxel resistance was associated with changes in
DNA methyltransferase activity and global methylation. Treat-
ment with decitabine alone did not alter response to docetaxel.
In contrast, TSA enhanced docetaxel sensitivity in MCF-7
cells whereas MDA-MB-231 cells were unaffected. Combination
4 EJC SUPPLEMENTS 8 (2010) 1–36
